Medical Oncology

, 30:369 | Cite as

EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer

  • Shaojun Zhu
  • Dake Chu
  • Yang Zhang
  • Xuxia Wang
  • Li Gong
  • Xiujuan Han
  • Li Yao
  • Miao Lan
  • Yanhong Li
  • Wei Zhang
Original Paper
First Online:
Received:
Accepted:

Abstract

EMMPRIN/CD147 has been proved to be associated with tumor invasion and metastasis in various human malignancies. In the present study, we investigated the expression of CD147 and its association with disease-free survival of colorectal cancer patients. CD147 expression was investigated in 328 cases of colorectal cancer by immunohistochemistry assay. Statistical analysis was utilized to evaluate the association of CD147 expression with disease-free survival of colorectal cancer patients. CD147 expression was proved to be increased in colorectal cancer (P < 0.001) and related to tumor invasion (P < 0.001), metastasis (P < 0.001), and TNM stage (P < 0.001). Kaplan–Meier showed CD147 was associated with disease-free survival of patients with colorectal cancer for patients with higher CD147 expression tend to have shorter disease-free survival (P < 0.001). Multivariate analysis also proved CD147 to be an independent prognostic factor for disease-free survival of colorectal cancer patients (P < 0.05). These results suggested the potential role of CD147 in relapse of human colorectal cancer. It might be a novel molecular marker to predict relapse of patients with colorectal cancer.

Keywords

CD147 Colorectal cancer Disease-free survival 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

This work was supported by The National Natural Science Foundation of China (No. 30672013 and No.81001088) and The National Basic Research Program (973 Program) of China (No. 2009CB521705).

References

  1. 1.
    Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Wang J. Current and future situation of colorectal carcinoma screening. J Dig Surg. 2006;5:303–5.Google Scholar
  3. 3.
    Wolpin BM, Meyerhardt JA, Mamon HJ, et al. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57:168–85.PubMedCrossRefGoogle Scholar
  4. 4.
    Gabison EE, Mourah S, Steinfels E. Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas. Am J Pathol. 2005;166:209–19.PubMedCrossRefGoogle Scholar
  5. 5.
    Yu XL, Hu T, Du JM, et al. Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem. 2008;283:18056–65.PubMedCrossRefGoogle Scholar
  6. 6.
    Luo J, Teplyakov A, Obmolova G, et al. Structure of the EMMPRIN N-terminal domain 1: dimerization via beta-strand swapping. Proteins. 2009;77:1009–14.PubMedCrossRefGoogle Scholar
  7. 7.
    Nakamura K, Kodama J, Hongo A, Hiramatsu Y. Role of EMMPRIN in endometrial cancer. BMC Cancer. 2012;12:191.PubMedCrossRefGoogle Scholar
  8. 8.
    Tang Y, Kesavan P, Nakada MT, Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase dependent generation of soluble EMMPRIN. Mol Cancer Res. 2004;2:73–80.PubMedGoogle Scholar
  9. 9.
    Vignesw N, Beckers S, Waigel S, et al. Increased EMMPRIN (CD147) expression during oral carcinogenesis. Exp Mol Pathol. 2006;80:147–59.CrossRefGoogle Scholar
  10. 10.
    Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Gabison EE, Hoang-Xuan T, Mauviel A, et al. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie. 2005;87:361–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Gu J, Zhang C, Chen R, et al. Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. Eur J Pediatr. 2009;168:705–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Nishibaba R, Higashi Y, Su J, et al. CD147-targeting siRNA inhibits cell-matrix adhesion of human malignant melanoma cells by phosphorylating focal adhesion kinase. J Dermatol. 2012;39:63–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhong X, Li M, Nie B, et al. Overexpressions of RACK1 and CD147 associated with poor prognosis in stage T1 Pulmonary Adenocarcinoma. Ann Surg Oncol. 2012 May 17.Google Scholar
  15. 15.
    Bi XC, Liu JM, He HC, et al. Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas. Clin Transl Oncol. 2012;14:190–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Piao S, Zhao S, Guo F, et al. Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma. J Cancer Res Clin Oncol. 2012;138:627–35.PubMedCrossRefGoogle Scholar
  17. 17.
    Pértega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer. 2011;11:312.PubMedCrossRefGoogle Scholar
  18. 18.
    Afonso J, Longatto-Filho A, Baltazar F, et al. CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis. Eur J Surg Oncol. 2011;37:811–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Liu F, Cui L, Zhang Y, et al. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat. 2010;124:677–88.PubMedCrossRefGoogle Scholar
  20. 20.
    Stenzinger A, Wittschieber D, von Winterfeld M, et al. High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer. Hum Pathol. 2012 Mar 12.Google Scholar
  21. 21.
    Zhu S, Li Y, Mi L, et al. Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma. Dig Dis Sci. 2011;56:3569–76.PubMedCrossRefGoogle Scholar
  22. 22.
    Fan Y, Meng S, Wang Y, et al. Visfatin/PBEF/Nampt induces EMMPRIN and MMP-9 production in macrophages via the NAMPT-MAPK (p38, ERK1/2)-NF-κB signaling pathway. Int J Mol Med. 2011;27:607–15.PubMedCrossRefGoogle Scholar
  23. 23.
    Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65:3193–9.PubMedGoogle Scholar
  24. 24.
    Marieb EA, Zoltan-Jones A, Li R, et al. EMMPRIN promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res. 2004;64:1229–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Yang JM, O’Neill P, Jin W, et al. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim. J Biol Chem. 2006;281:9719–27.PubMedCrossRefGoogle Scholar
  26. 26.
    Pan Y, He B, Song G, et al. CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells. Oncol Rep. 2012;27:2003–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Shaojun Zhu
    • 1
  • Dake Chu
    • 2
    • 6
  • Yang Zhang
    • 3
  • Xuxia Wang
    • 4
  • Li Gong
    • 1
  • Xiujuan Han
    • 1
  • Li Yao
    • 1
  • Miao Lan
    • 1
  • Yanhong Li
    • 1
    • 5
  • Wei Zhang
    • 1
  1. 1.The Helmholtz Sino-German Research Laboratory for Cancer, Department of PathologyTangdu Hospital, the Fourth Military Medical UniversityXi’anPeople’s Republic of China
  2. 2.State Key Laboratory of Cancer Biology, Department of Gastrointestinal Surgery, Xijing Hospital of Digestive DiseasesThe Fourth Military Medical UniversityXi’anChina
  3. 3.State Key Laboratory of Cancer Biology, Cell Engineering Research Centre and Department of Cell Biology, National Key Discipline of Cell Biologythe Fourth Military Medical UniversityXi’anChina
  4. 4.Department of Gastroenterology, Tangdu Hospitalthe Fourth Military Medical UniversityXi’anChina
  5. 5.Department of Gynecology and Obstetrics, Tangdu Hospitalthe Fourth Military Medical UniversityXi’anChina
  6. 6.State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular BiologyThe Fourth Military Medical UniversityXi’anChina

Personalised recommendations